Effect of Clonidine, Yohimbine and Nalterexone on polycystic ovary syndrome patients

Comparison the therapeutic effect of Clonidine, Yohimbine and Nalterexone on removing the ovarian cyst in poly-cystic ovary syndrome patients referred to Valie-Asre Clinical Center, Imam Khomeini Hospital, Tehran

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201204027883N4

Enrollment

Registered

2012-05-23

Start date

2012-04-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome. Sclerocystic ovary syndrome Stein-Leventhal syndrome

Interventions

Intervention 1: Nalterxone capsule 50 mg. after dinner. Intervention 2: Clonidine tablet 0.2 mg. twice 0.1 mg. after breakfast and dinner. Intervention 3: Yohimbine tablet 0.5 mg. after dinner. Interv

Treatment - Drugs

Nalterxone capsule 50 mg. after dinner

Clonidine tablet 0.2 mg. twice 0.1 mg. after breakfast and dinner.

Yohimbine tablet 0.5 mg. after dinner.

Control group: Placebo, capsule without drug.

Eligibility

Sex/Gender

Female

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: female, age20-40 and they are suffering of Polycystic ovary syndrome exclusion criteria:Body Mass Index:28, without basis disease and must not use drug.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Estradiol,LH/FSH and Insuline. Timepoint: before intervention and after two mounts of it. Method of measurement: Utilization of diagnosis kite of Elisa.	—

Secondary

Measure	Time frame
Adrenaline, Noradrenaline,Beta endorphine and Cortisol. Timepoint: Before intervention and two mounts of it. Method of measurement: Utilization of diagnosis Elisa kite.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Younessian

Research managment

research@tums.ac.ir+98 21 8163 3513

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026